XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

XTalks

JULY 25, 2023

Kelly Warfield, Emergent’s senior vice president, science and development, in the company’s press release. Anthrax is a rare, yet severe disease caused by the bacterium B. The non-inferiority of Cyfendus to BioThrax was statistically determined in the clinical study results. What Is Anthrax? Additionally, at Day 64, 86.6

FDA Approval 98

FDA Approval Vaccination Vaccine Antibody 98

XTalks

JULY 28, 2021

Compared to Vaxneuvance’s targeting of 15 different strains of the bacterium, Pfizer’s shot protects against 20. Both next-gen shots offer enhanced protection against bacteria that can cause pneumonia, blood infections and meningitis. This is seven more strains than its current winning vaccine Prevnar 13, which registered $5.95

FDA Approval 89

FDA Approval Vaccination Vaccine Immune Response 89

XTalks

JANUARY 20, 2021

To test their hypothesis in the lab, the researchers infected mice with a stomach bacterium and fed them a protein found in egg white called ovalbumin at the same time (this protein is commonly used as a typical model food antigen in experiments). The antihistamine treatment is currently being evaluated in larger clinical trials.

Immune Response 52

Immune Response Research Allergies Protein 52

XTalks

AUGUST 2, 2023

With Blackstone Life Sciences, up to €300 million (around $315 million USD) will be invested to accelerate pivotal studies and clinical development programs for formulating the subcutaneous delivery of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma. billion ($3.65 billion ($2.85 billion ($19.19

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

NOVEMBER 10, 2020

Originally published on July 15, 2020: Quebec-based biotechnology company Medicago has developed a plant-derived vaccine for COVID-19 that is now undergoing early-stage clinical trials. The Phase I trials will evaluate the safety of the plant-based vaccine in a cohort of 180 healthy men and women between the ages of 18 and 55.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

XTalks

DECEMBER 24, 2020

The pandemic propelled the life science and healthcare sectors onto center stage, and they rose to the occasion against the most unprecedented health challenge in recent times. While COVID-19 has undoubtedly been the biggest story in the life science industry in 2020, it was a busy and positive year in many other areas.

Life Science 111

Life Science Vaccination Vaccine Gene 111